Coeptis和Z Squad的兼并接近完成,建立了一个有税收优惠的新实体,有待Nasdaq批准。 Coeptis and Z Squared's merger nears completion, creating a new entity with tax benefits and pending Nasdaq approval.

截至2026年3月,Coeptis治疗公司和Z Squad Inc.的合并工作已接近完成,大多数监管和程序步骤已经完成。 As of March 2026, the merger between Coeptis Therapeutics and Z Squared Inc. is nearing completion, with most regulatory and procedural steps finalized. Coeptis股东将获得Z Squad新实体的股份,并保留与Gear治疗公司(一家无脊椎生物科技公司)接触的机会。 Coeptis shareholders will receive shares in the new Z Squared entity and retain exposure to Gear Therapeutics, a spun-off biotech firm. Z Squad是一家拥有9 800个ASIC采矿单位的数字基础设施公司,受益于美国批准的Dogecoin ETFs和1亿美元的Coeptis净营业损失转帐,提供了巨大的税收优惠。 Z Squared, a digital infrastructure company with 9,800 ASIC mining units, benefits from U.S.-approved Dogecoin ETFs and a $100 million transfer of Coeptis’s net operating losses, providing significant tax advantages. 这笔交易正在等待最后的Nasdaq上市批准,如获准,预计将在Nasdaq或OTC市场进行交易。 The deal awaits final Nasdaq listing approval, with trading expected on Nasdaq or OTC Markets if approved.